EXPLORE


0.0
0.0
0%
$10 USD / Hour
・

Portugal (2:25 AM)
・
Joined on May 3, 2010
$10 USD / Hour
・
A highly qualified researcher and educator with more than 20 years of experience in a wide variety of topics in health, science and medicine. An experienced author, invited reviewer, thesis advisor, and proof-reader adept at successfully communicating with audiences of varying levels of expertise in Portuguese, English, and Spanish. Excellent analytical skills and attention to detail leveraged to ensure clarity and understanding of all written/visual materials. A track record of utilizing organisational and administrative skills to prioritise tasks and meet obligations/deadlines on time and on budget. Practiced at working in high-pressure, high-stakes environments. AREAS OF EXPERTISE Clinical Research & Development Published Article/Book Chapter Author Invited Reviewer Proof-reader Microbiology/Parasitology Mycology/ Virology Biochemistry/Oncology Medicine/Immunology Hygiene/Environmental Health Nursing/Pharmacy Clinical Analysis/Dietetics
Verifications
CV
CV
No reviews to see here!
Education
Universidade do Porto
2006 - 2010
•
4 years
Clinical Microbiology PhD

Portugal
2006 - 2010
•
4 years
Publications
se of Helicobacter pylori-specific antibodies in the ....
Br J Biomed Sci. 2003;60(4):175-9.
This study aims to assess the usefulness of H. pylori diagnosis in patients with chronic gastritis (CG), intestinal metaplasia (IM) and dysplasia--conditions that are associated with gastric cancer. In conclusion, it is suggested that non-invasive serological evaluation of anti-H. pylori (IgG) status after eradication therapy for peptic ulcer disease could be extended, after proper assessment of cut-off values and their validation, to the follow-up of patients with CG and IM.
A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia.
J Clin Pathol. 2004 Feb;57(2):177-82
AIM: To devise a follow up model for patients with gastric cancer associated lesions, such as atrophic chronic gastritis (ACG) and intestinal metaplasia (IM). CONCLUSION: Patients with ACG or IM could possibly be allocated to different management schedules, based on differences in rate and proportion of progression to LGD or HGD. Patients with type III IM may benefit from six to 12 monthly improved endoscopic examination (magnification chromoendoscopy).
Validity of serum pepsinogen I/II ratio for the diagnosis of .....
Neoplasia. 2004 Sep-Oct;6(5):449-56
A cohort of individuals (n = 136) with lesions as severe as atrophic chronic gastritis (ACG) was cross-sectionally evaluated for the validity assessment of pepsinogen I (PGI) and pepsinogen II (PGII) serum levels for the diagnosis of intestinal metaplasia (IM) and gastric dysplasia. PGI/PGII serum level ratio can be used even in the management of patients with a high a priori probability for a positive test.